Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Snapback Rally Sends Axovant Sciences 10% Higher Today

By Todd Campbell - Sep 27, 2017 at 4:33PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares are gaining back some ground, after tumbling 70% yesterday on news that the company's lead drug in development failed in a key phase 3 study.

What happened

One day after shares collapsed 70% in the wake of a disappointing trial failure in Alzheimer's disease, Axovant Sciences ( AXGT -3.77% ) is bouncing back by 10% at 3:45 pm EDT today.

So what

Axovant Sciences' long-shot bet that it could profit from resurrecting the Alzheimer's-disease drug intepirdine has failed to pay out.

Bundled paper money inside a large drug capsule

IMAGE SOURCE: GETTY IMAGES.

The company acquired intepirdine from GlaxoSmithKline's discard bin for $5 million, milestones, and potential royalties in 2015. Shortly thereafter, it launched a pivotal study of the drug in patients with mild to moderate Alzheimer's disease.

On Tuesday, management reported that despite carefully planning intepirdine's phase 3 trial for success, the drug failed to outperform placebo on two key Alzheimer's-disease rating scales.

The disappointing news sent Axovant Sciences' shares reeling, but bargain hunters bid up shares today on the hope that two other ongoing studies might pan out better. The first is a phase 2b study evaluating intepirdine in patients who have dementia with Lewy bodies (DLB). A second phase 2 study in the same indication is evaluating a different drug, nelotanserin.

AXON Market Cap Chart

AXON Market Cap data by YCharts.

Now what

Dementia with Lewy bodies is the second most common cause of dementia in elderly Americans, and currently, there aren't any treatments for it approved by the U.S. Food and Drug Administration. The miss in Alzheimer's disease casts significant doubt on intepirdine's ability to help DLB patients, but there's always a chance that this study is a success. Results are anticipated prior to the end of this year.

Although it may be tempting to buy shares in Axovant Sciences following its big drop, the stock has become incredibly risky ahead of the DLB data. Also, despite the drop, the company's market cap is still more than twice the company's cash on its books, suggesting shares could still fall significantly still if the DLB trials disappoint. For this reason, most investors ought to focus on other less-risky stocks to buy.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Axovant Gene Therapies Ltd. Stock Quote
Axovant Gene Therapies Ltd.
AXGT
$1.53 (-3.77%) $0.06

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
635%
 
S&P 500 Returns
141%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/02/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.